The Parathyroids

Intervention (MORE), and Lilly's registration trial of recombinant PTH(1-34) in the treatment of postmenopausal women with osteoporosis. In 2001. Dr. Marcus joined the US Affiliate of Eli Lilly & Company to support Lilly's program in Osteoporosis and Skeletal Medicine. From 2003 until his retirement from Lilly in 2008, Dr. Marcus was the lead physician for the Forteo team at Lilly. He has published more than 150 research papers, editorials, and reviews. Dr. Marcus served as President of the American Society for Bone & Mineral Research in 2000-2001. Dr. Michael A. Levine is Chief of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children's Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair and is Professor of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine. Dr. Levine's research focuses on the genetic basis of disorders of bone and mineral metabolism and complements his clinical expertise in endocrine diseases that affect bone and mineral metabolism. His approach is to apply molecular and genetic tools to analyze the basis of altered hormone action, particularly in G protein-coupled signal transduction systems that affect growth and development. He has identified or contributed to the molecular basis of several inherited disorders of bone and mineral metabolism, including familial hypoparathyroidism, pseudohypoparathyroidism, cherubism, and the McCune Albright syndrome. His research interests now extend to the molecular events that control embryological development of the parathyroid glands and genetic modifiers of vitamin D action. Claudio Marcocci, MD, is Professor of Endocrinology at the Department of Clinical and Experimental Medicine, Director of the Postgraduate School in Endocrinology and Metabolism, University of Pisa and Director of the Endocrine Unit 2, University Hospital of Pisa. Over the years he has combined its clinical appointments with basic, translational and clinical research in the fields of parathyroid and thyroid diseases and vitamin D. Over the last 10 years he has contributed original work on the management of Graves' orbitopathy, the calcium sensing receptor, clinical aspects of primary hyperparathyroidism and hypoparathyroidism and the molecular mechanisms of parathyroid tumorigenesis. Member of several Scientific Associations: Italian Society of Endocrinology, Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases, European Thyroid Association, American Thyroid Association, Endocrine Society, American Society of Bone and Mineral Research, American Association of Clinical Endocrinologists. Shonni J. Silverberg, MD, is an endocrinologist in New York and is affiliated with?New York-Presbyterian Hospital-Columbia and Cornell. She received her medical degree from Weill Cornell Medical College of Cornell University and has been in practice for more than 20 years. She is Professor of Clinical Medicine, Division of Endocrinology, Departments of Medicine and Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. John T. Potts, Jr., MD, is currently the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. After medical training at the University of Pennsylvania, he completed his internship and residency at Massachusetts General Hospital. He went on to work at the National Institutes of Health (NIH), studying protein chemistry with Nobel laureate Christian Anfinsen. Dr. Potts remained at the NIH from 1959 until 1968, when he returned to the MGH as chief of endocrinology. The author or co-author of more than 500 scientific publications, he is a member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. He is also a director of ReceptorBase, Inc. and Zeltiq Aesthetics, a founder of Radius Health, Inc., and a member of the Scientific Advisory Boards of MPM Capital and HealthCare Ventures, as well as the Medical Advisory Board of Cell Genesys